Patient characteristics
| . | IL-1RA . | Placebo . |
|---|---|---|
| No. | 96 | 90 |
| Median age (range), years | 41 (3-59) | 44 (8-64) |
| Sex | 49M/47F | 52M/39F |
| Stem cell source | ||
| Bone marrow | 82 | 76 |
| PBSC | 14 | 14 |
| Histocompatible family member | 61 | 57 |
| 5/6 matched family member or unrelated donor | 35 | 33 |
| Diagnosis* | ||
| CML | 48 | 38 |
| ALL | 5 | 8 |
| AML | 17 | 23 |
| MDS | 12 | 10 |
| Myeloma | 1 | 1 |
| NHL | 7 | 7 |
| PNH | 2 | 0 |
| CLL | 3 | 2 |
| Other | 2 | 0 |
| . | IL-1RA . | Placebo . |
|---|---|---|
| No. | 96 | 90 |
| Median age (range), years | 41 (3-59) | 44 (8-64) |
| Sex | 49M/47F | 52M/39F |
| Stem cell source | ||
| Bone marrow | 82 | 76 |
| PBSC | 14 | 14 |
| Histocompatible family member | 61 | 57 |
| 5/6 matched family member or unrelated donor | 35 | 33 |
| Diagnosis* | ||
| CML | 48 | 38 |
| ALL | 5 | 8 |
| AML | 17 | 23 |
| MDS | 12 | 10 |
| Myeloma | 1 | 1 |
| NHL | 7 | 7 |
| PNH | 2 | 0 |
| CLL | 3 | 2 |
| Other | 2 | 0 |
CML (chronic myeloid leukemia) includes stable phase, accelerated phase, or blast transformation. ALL/AML (acute lymphocytic leukemia/acute myeloid leukemia) includes patients in first, second, or subsequent remission. MDS (myelodysplastic syndrome) includes patients with RA/RARS (refractory anemia/refractory anemia with ringed sideroblasts), RAEB (refractory anemia with excess of blasts), CML (chronic myeloid leukemia), and RAEB-T (refractory anemia with excess of blasts in transformation). NHL indicates non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; CLL, chronic lymphocytic leukemia; and PBSC, peripheral blood stem cell.